Loading...
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
BACKGROUND: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb response) and safety of roxadustat in anemic nondialysis-dependent chronic kidney disease (NDD-CKD) subjects. METHODS: NDD-CKD sub...
Na minha lista:
| Udgivet i: | Nephrol Dial Transplant |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4569392/ https://ncbi.nlm.nih.gov/pubmed/26238121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfv302 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|